Linsitinib showed significant efficacy in reducing proptosis in TED patients, with a 52% responder rate at 150mg BID. The ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

The iDose platform is designed to address ubiquitous patient non-adherence and chronic side effects associated with topical ...

Andrew G. Lee, MD, and Andrew Carey, MD, return for this latest episode of the NeuroOp Guru to discuss whether a dead nerve ...

InflammX’s pipeline includes an orally dosed therapeutic candidate targeting intermediate age-related macular degeneration ...

The phase 1 clinical trial is a multicenter, open-label, dose-escalation study to assess drug safety via intravitreal ...

New features include simultaneous calculation for both eyes, access to toric and non-toric results, and improved theater view design.

AI-based screening for pediatric DRD is more cost-effective and increases screening rates compared to traditional ECP methods ...

Study sees a positive association between the dietary inflammatory index (DII) and non-refractive visual impairment among US ...

RhyGaze, a biotechnology company based in Basel, Switzerland, and Philadelphia, PA, secured Series A financing of $86 million ...

City Therapeutics will develop a novel RNAi clinical candidate toward a specific disease target for intravitreal ...

Panelists discuss how successful implementation of the port delivery system requires careful attention to surgical technique ...